<DOC>
	<DOCNO>NCT00698490</DOCNO>
	<brief_summary>The purpose study compare , healthy HSV seronegative HSV seropositive subject , humoral cellular immune response herpes simplex candidate vaccine contain gD two different cell line use gD-Alum control .</brief_summary>
	<brief_title>Humoral Cellular Immune Response Herpes Simplex ( gD ) Candidate Vaccines From 2 Different Cell Lines</brief_title>
	<detailed_description>At time conduct study , sponsor GlaxoSmithKline know former name SmithKline Beecham .</detailed_description>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Between 18 45 year age Written inform consent Female volunteer must use contraception avoid become pregnant duration vaccination course Serology : Groups 1 , 3 , 4 5 : HSV1 AND HSV2 seronegative ( gD2 ELISA ) ; Group 2 : HSV seropositive gD2 ELISA entry Any previous vaccination Herpes simplex . Any previous administration MPL . Pregnancy lactation . Patient immunocompromised receive immunomodifying therapy kind . Clinical sign acute febrile illness time entry study . Any administration immunoglobulins vaccination course within one month vaccination . Any vaccination within one week study vaccination . Previous know hypersensitivity vaccination component vaccine . Simultaneous participation clinical trial investigational drug vaccine . Subjects currently followup period vaccine study include . Recent history alcoholism drug abuse ( within past 6 month ) . Lifethreatening serious cardiac ( NYHA grade IIIIV ) , gastrointestinal , hepatic , renal , hematological immunological disorder , opinion investigator , would preclude entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Herpes simplex</keyword>
	<keyword>Herpes simplex candidate vaccine</keyword>
</DOC>